Seno

SAN ANTONIO, TEXAS – January 22, 2009 – Seno Medical Instruments, Inc., today announced the appointment of Walter Robb (PhD) to its Scientific Advisory Committee.

SAN ANTONIO, TEXAS – December 8, 2008 – Seno Medical Instruments, Inc., today announced the appointment of William F. Keane, M.D. as its Chief Medical Officer.

SAN ANTONIO, TEXAS – November 20, 2008 – Seno Medical Instruments, Inc., today announced the official signing of a licensing agreement with VisualSonics (www.visualsonics.com), a world-leader in preclinical high-frequency ultrasound, for the exclusive rights to Seno’s Opto-Acoustic small animal imaging (preclinical) technology.

SAN ANTONIO, TEXAS — July 1, 2008 – Seno Medical Instruments, Inc., of Texas, The University of Prince Edward Island, and Ryerson University of Toronto, officially celebrated the formation of an exciting research partnership that has great potential to benefit human and animal health at a public ceremony held June 25, 2008 at Prince Edward Island.

Clinical Model of Novel Opto-Acoustic Platform Technology Also Under Development

SAN ANTONIO, TEXAS — June 18, 2008 – Seno Medical Instruments, Inc., a San Antonio company engaged in the development of opto-acoustics, the next generation cancer imaging technology, today announced the appointment of Thomas F. Budinger, M.D. to the company’s Scientific Advisory Committee.

SAN ANTONIO, TEXAS — May 13, 2008 – Seno Medical Instruments, Inc., a San Antonio company engaged in the development of opto-acoustics, the next generation cancer imaging technology, today announced the appointment of William F. Keane, M.D. to the company’s Scientific Advisory Committee.

SAN ANTONIO, TEXAS — April 8, 2008 – Seno Medical Instruments, Inc., a San Antonio company engaged in the development of opto-acoustics, the next generation cancer imaging technology, received the prestigious Super Star Award from the San Antonio Technology Accelerator Initiative (SATAI) in recognition for their entrepreneurial development of cutting edge technology in the region.

SAN ANTONIO, TEXAS — February, 2008 – Seno Medical Instruments, Inc., a San Antonio company engaged in the development of medical devices announces the appointment of Patricia E. Sacks, M.D. to its Scientific Advisory Committee. Dr. Sacks, a breast-imaging radiologist who has been in practice for more than 30 years, now joins an elite group of professionals and medical specialists who are dedicated to the early detection of cancer.

San Antonio is getting good at homegrown startup companies in the biotech field, but acquisitions have meant few biomedical corporate headquarters have stayed in town. In recent years, larger companies have bought out at least three companies with promising technology and patents.

SAN ANTONIO, TEXAS – January 9, 2008 – Seno Medical Instruments, Inc., a company engaged in the development of medical devices for cancer, announced receipt of the remaining $1 million from the Texas Emerging Technology Fund (TETF). This award is one of the largest investments the State of Texas has made to date into a private company.

SAN ANTONIO, TEXAS — August 21, 2007 – Seno Medical Instruments, Inc., a company engaged in the development of medical devices announced a $2 million dollar award from the Texas Emerging Technology Fund (TETF). This funding will allow the company to further develop its life saving technology for cancer imaging and detection and move it closer to the global marketplace.

SAN ANTONIO, TEXAS—July 13, 2007—Seno Medical Instruments, Inc., a San Antonio company engaged in the development of medical devices announces the appointment of Lester Crawford, Ph.D., D.V.M. to its Scientific Advisory Committee. Dr. Crawford, widely known for his experience as Deputy Commissioner and Commissioner at the Food and Drug Administration between 2002 and 2005, joins a prestigious group of professionals dedicated to the early detection of cancer.

SAN ANTONIO, TEXAS—June 12, 2007—Seno Medical Instruments, Inc., a San Antonio company engaged in the development of medical devices announces the selection of John Holaday, PhD to its Scientific Advisory Committee. Dr. Holaday, formerly listed among the 500 most cited scientists in the world by the Science Citation Index, will be instrumental in Seno Medical’s efforts to bring its patented breast cancer diagnostic technology to the global marketplace.